Lens

6613
13.2803.28% ( -0.450 )
Delay Closed: Nov 16, 16:08:11

Overview

Lens (6613)

Lens Technology Co., Ltd. engages in the research and development, production, and sale of structural components, functional modules, complete machine assembly,...

Open
13.730
High
13.730
Low
13.190
Prev. Close
13.730
Volume
3.68M
Turnover
49.09M
Avg Price
13.330
Bid/Ask Ratio
-31.25%
Amplitude
3.93%
52wk High
31.954
Volume Ratio
0.24
Turnover Ratio
1.22%
52wk Low
12.250
HK Mkt Cap
4.01B
Market CapHKD
70.10B
P/ETTM
23.19
P/EDynamic
31.79
P/EStatic
--
EPSTTM
0.573
EPSDynamic
0.418
EPSStatic
--
BVPS
11.72
P/B
1.13
HK Shares
301.60M
Dividend YieldTTM
4.71%
DividendTTM
0.626
Shares
5.28B
Min lot size
200
Currency
HKD

Lens Analyst Rating

View more

Forecast & Rating

Oct 27, 2026
Price forecast
HK$26.3498.36%
Forecast & RatingStrong buy
8analysts
  • Strong buy75.00%
  • Buy25.00%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 9

    News that Lens Technology's first TGV glass-substrate pilot line is slated for completion by year-end lifted the H-shares as much as 7% intraday to HK$14.61 before fading to a HK$14.21 close, up 4.03% from the prior HK$13.66. Morgan Stanley added roughly 382,200 shares near HK$13.79 and JPMorgan about 685,400 shares near HK$14.87. That move sits uneasily against Q3 numbers: revenue of HK$22.27bn fell 1.58% yoy and net profit of HK$986m with EPS of HK$0.1865 both dropped about 47%, so earnings have not kept pace with the rebound. The stock is still down 45.09% year-to-date, 56.38% below its 52-week high of HK$32.58, trades under its MA20 of 15.61 and MA60 of 20.29, and sits only 16% above the November 2 low of HK$12.25. Nomura, though, stays cautious on the Apple supply chain and expects iPhone output to decline next year.

  2. Nov, 6

    Nomura's cautious stance on the Apple supply chain and its expectation of lower iPhone output next year weighed on the whole handset complex, and Lens Technology fell 4.94% to HK$13.66 after probing HK$13.34 intraday and failing to hold a rebound to HK$13.82; turnover was HK$124.5 million on 9.12 million shares, a 3.03% turnover rate. The slide squares with Q3 revenue of HK$22.27 billion, down 1.58% year on year, while net profit of HK$986 million was cut 46.93% and the net margin eased to 4.43% from 4.93% in Q2, as newer businesses have yet to take over. The stock is down 47.22% year to date, 58.07% below its 52-week high of HK$32.58 and still well under its MA20 of HK$15.91 and MA60 of HK$20.41, though it sits 11.51% above the 2 November low of HK$12.25. Still, Morgan Stanley and JPMorgan added roughly 382,200 and 685,400 shares near HK$13.79 and HK$14.87 respectively.

  3. Nov, 5

    Lens Technology rebounded from an intraday low of HK$13.53 in the morning session to close up 5.27% at HK$14.37, touching HK$14.40 late in the afternoon, as Morgan Stanley disclosed raising its stake by about 382,200 shares at roughly HK$13.79 and JPMorgan added some 685,400 shares near HK$14.87, while southbound flows ended a sustained selling streak and lifted Hong Kong sentiment. Fundamentals have not followed: Q3 2026 revenue of HK$22.27 billion fell 1.58% year on year, net profit of HK$986 million dropped 46.93%, and the net margin stood at 4.43%, with robotics and AI-glasses businesses not yet large enough to offset the core handset business. The shares are still down 44.47% year to date, 55.89% below the 52-week high of HK$32.58 set on January 25, and trade under both the MA20 of HK$16.27 and MA60 of HK$20.54, at 25.1x PE and 1.23x PB. Whether the institutional buying persists is the open question.

  4. Nov, 4

    Lens Technology staged a low-then-high session, dipping to HK$12.43 at 09:49 before a one-way afternoon rally to HK$13.67 at 15:37 and a HK$13.65 close, up 8.8% on HK$205 million turnover, with afternoon volume of 11.54 million shares accounting for more than 70% of the day's 15.60 million. The rebound was driven by JPMorgan lifting its stake by roughly 685,400 shares at about HK$14.87, southbound capital ending its selling streak, and robotics-related interest after QUANTGROUP signed a three-way strategic cooperation with Lens. Fundamentals still cut the other way: third-quarter net profit attributable to shareholders halved year on year as new businesses have yet to fully take over, the stock hit a 52-week low of HK$12.25 on 2 November, is down 47.26% year to date, sits 58.1% below its HK$32.58 52-week high and remains under its MA20 of HK$16.64 and MA60 of HK$20.65. Though Apple's latest quarter beat expectations, rising memory cost pressure on the supply chain is a variable to watch.

  5. Nov, 3

    Lens Technology reversed an early gain and closed at HK$12.55, down 3.24% from HK$12.97, as attention after Apple's latest quarterly report turned to intensifying memory cost pressure in coming quarters, dragging the handset supply chain lower; the third quarter added to that, with net profit of HK$986 million halving 46.9% year on year on revenue of HK$22.27 billion, down 1.58%, as new businesses have yet to fully take over. The stock touched HK$12.96 at 10:05 before sliding through the afternoon session to HK$12.26 at 14:16, ending just 2.45% above its 52-week low of HK$12.25 set on 2 November; it is down 51.51% year to date and 61.48% below the 25 January high of HK$32.58, far under its MA20 of 17.05 and MA60 of 20.78. Still, founder Zhou Qunfei reclaimed the title of China's richest woman, and the company signed a tripartite strategic cooperation with QUANTGROUP and Super New Era.

News

Bullish vs. Bearish — Last 3 Months

21.2k followers · 2 opinions
▲Bullish100%
  • F
    Fattycat

    $Lens(06613.HK)

    Lens Technology Q2 2026: Strong Recovery Underway!

    Lens Technology is bouncing back☺️

    Q2 delivered RMB 14.73 billion revenue and RMB 726 million profit, with gross margin jumping to 18.2%.

    Growth Engines Firing:

    ✅ Automotive: +6.6% YoY

    ✅ AI Glasses & Wearables: +8.0% YoY

    ✅ Other Smart Terminals: +47.0% YoY

    Smartphone headwinds persist (-17.7%) but diversification is paying off- automotive, AI and robotics are taking the lead. 💪

    The known Big News: Partnership with Intel on advanced glass substrate tech puts them at the cutting edge of next-gen semiconductor packaging! 🚀

    They are more than just a consumer electronics supplier -the future looks bright! ✨

    Not financial advice. I find this company interesting and following up with the latest earnings and development. Please do your own DD if you want to invest in it ☺️.

    From Glass LENS Q2 RECOVERY, ENABLING A SMARTER LENS ToA Smarter Lens Technology
  • F
    Fattycat
    Featured

    $Lens(06613.HK)

    Is Lens Technology Hong Kong’s most under‑the‑radar AI hardware pick? 🤔

    Most investors only see it as Apple’s glass supplier, but it has quietly grown far beyond just making phone parts.

    It now counts top names like Apple, Samsung, Xiaomi, Honor, OPPO, vivo and a growing list of global automakers as customers. Currently, Apple is still their biggest client and Lens is steadily branching out into car displays, smart wearables and AI hardware.

    What really stands out is its compelling valuation: trading at roughly 12x earnings and 1.2x book value, well below most hardware peers.

    It also has a rock‑solid balance sheet, low debt, plenty of cash and steady free cash flow.

    The latest big news?

    A strategic MOU with Intel to develop next‑gen glass substrates and Through‑Glass Via (TGV) tech for advanced AI chip packaging.

    This is a non‑binding deal with no guaranteed revenue now but it opens the door to one of the semiconductor industry’s most exciting long‑term breakthroughs.

    If this works out, Lens could step right from consumer electronics into the fast‑growing AI semiconductor supply chain.

    Great finances, premium customers, cheap valuation and AI upside — definitely one to keep watching!

    Not financial advice. Do your own DD☺️

    LENS TECHNOLOGY (HKEX:6613) 蓝思科技 LENS TECHNOLOGY From Smartphone Glass Leader to
  • H
    Hardik Shah

    ⚡ 𝐔𝐏𝐃𝐀𝐓𝐄: $Tempus AI(TEM.US) Tempus AI Launches Next-Generation 𝐋𝐞𝐧𝐬 Agentic AI Platform

    👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:

    ➤ Tempus AI unveils next-generation 𝐋𝐞𝐧𝐬 to accelerate drug development.

    ➤ Platform integrates multimodal data, 𝐀𝐈 𝐚𝐠𝐞𝐧𝐭𝐬, and scientific workflows.

    ➤ Built on over a decade of 𝐫𝐞𝐚𝐥-𝐰𝐨𝐫𝐥𝐝 𝐝𝐚𝐭𝐚 and oncology expertise.

    ➤ Supports analysis across 𝟖.𝟓𝐌+ de-identified patient records.

    ➤ Users can generate and execute complex 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐩𝐥𝐚𝐧𝐬 using natural language.

    ➤ Already utilized by 𝟏𝟗 of the top 𝟐𝟎 global biopharma companies.

    ➤ Platform aims to speed clinical trial design, biomarker validation, and evidence generation